Bioavailability of Mirikizumab Formulations in Healthy Volunteers

Phase 1, randomised, open-label trial of mirikizumab in ulcerative colitis (UC) and Crohn's disease (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Dose-normalized Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at 2016 hours and Dose-normalized Area Under the Serum Concentration-Time Curve From Time Zero to Infinity at 2016 hours. Started Jun 2017; status: completed.